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Introduction
In the majority of patients with multiple sclerosis (MS), 
neuronal cell bodies and axons degenerate in the context of 
inflammation and demyelination, leading to a gradual 
decline in neurological function (progression).1 A gathering 
body of evidence from post-mortem tissue-based studies of 
progressive MS and models of MS consistently indicate a 
role for mitochondria in the dysfunction and degeneration 
of neurons.2–5 However, mitochondria and mitochondrial 
DNA (mtDNA) have not been investigated in detail in non-
central nervous system (CNS) tissue in MS, particularly 
post-mitotic cells such as skeletal muscle fibres.
Mitochondria are the most efficient producers of 
energy in the form of ATP. The mitochondrial respiratory 
chain consists of five complexes, each made up of multi-
ple subunits.6 These subunits are encoded by both mtDNA 
and nuclear DNA. In patients with mtDNA deletions and 
mtDNA depletion, not all complexes of the mitochondrial 
respiratory chain are affected; complex IV is frequently 
impaired while complex II is spared or increased (respira-
tory enzyme deficiency), as the latter is encoded entirely 
by the nuclear DNA.7 Cells without complex IV activity 
can be identified in tissue using histochemistry, in con-
trast to those lacking complex I, for single cell-based 
studies. We recently identified mtDNA deletions at high 
levels, arising through clonal expansion, in respiratory 
enzyme-deficient cortical neurons and choroid plexus 
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epithelial cells in progressive MS, while others described 
a decrease in transcripts of mitochondrial respiratory 
chain subunits encoded by nuclear DNA.2–5,8 A high level 
of mtDNA deletions is necessary to impair the biochemi-
cal activity of respiratory chain complexes, as each cell 
contains multiple copies of mtDNA. Clonal expansion of 
the mtDNA deletion is the process by which an mtDNA 
deletion reaches high levels in a single cell.9 This phe-
nomenon occurs in post-mitotic cells, including neurons 
and muscle fibres, with ageing and in disease.10 If the 
CNS mtDNA deletions seen in MS were part of a diffuse 
multisystem process, they would be detectable within res-
piratory enzyme-deficient skeletal muscle, a key tissue in 
the diagnosis of mitochondrial disease.11
In this study, we investigated single fibres in paraspinal 
muscles from progressive MS cases, known to harbour an 
excess of mtDNA deletions in the CNS, to determine 
whether the respiratory enzyme deficiency and mtDNA 
deletions were also present in excess of age-related changes 
within muscle.
Materials and methods
Case details
A total of 17 progressive MS cases, where snap-frozen 
CNS tissue was also available (except MS09), and 15 age-
matched controls were used for this study (Table 1). A fam-
ily history suggestive of a primary mitochondrial disorder 
was not present and in controls there was no evidence of a 
neurodegenerative disorder, including Parkinson’s disease 
(PD). MS cases (except MS09) were non-ambulatory and 
all the controls remained mobile. All post-mortem muscle 
(multifidus) from MS and controls were obtained from the 
United Kingdom (UK) MS and PD tissue bank and stored 
at −80°C. The peri-operative samples were obtained from 
lumbar paraspinal and deep cervical paraspinal muscles. 
Ethical approval was granted for this study (09/H0906/81).
COX/succinate dehydrogenase (SDH) histochemistry
Cytochrome c oxidase or COX (100 µm cytochrome c, 4 
mM diaminobenzidine tetrahydrochloride and 20 µg/ml 
catalase in 0.1 M phosphate buffer at pH 7.0) and SDH 
(130 mM sodium succinate, 200 mM phenazine methosul-
phate, 1 mM sodium azide, 1.5 mM nitroblue tetrazolium in 
0.1 M phosphate buffer pH 7.0) histochemistry was per-
formed on cryostat sections (15 µm thickness) sequentially 
(COX/SDH) in all cases, as previously stated.12
Immunohistochemistry
Immunohistochemistry was performed on serial cryostat 
sections to those subjected to histochemistry. Sections were 
air dried for one hour and fixed in 4% paraformaldehyde 
(PFA) for 10 minutes. The tissue was then permeabilised in 
a graded methanol series with additional 0.3% H2O2. 
Primary antibodies were applied for 90 minutes and visual-
ised using Menapath X-Cell Plus Polymer detection system 
(A. Menarini Diagnostics, Wokingham) and DAB chromo-
gen (Supplementary Table 1).
Laser-microdissection, real-time polymerase 
chain reaction (PCR), long-range PCR and 
mtDNA deletion breakpoints
Single respiratory-deficient and respiratory-intact (with 
complex IV activity) muscle fibres were laser microdis-
sected (Leica). The MTND1/MTND4 assay13 was used to 
establish: 1) the level of mtDNA deletions in single respira-
tory enzyme-deficient and respiratory enzyme-intact muscle 
fibres, and 2) wild-type (MTND1 Ct values) and total 
mtDNA copies (MTND4 Ct values) in the same cell. A 
standard curve for both MTND1 and MTND4 copies was run 
alongside, in triplicates, as well as control standards where 
the mtDNA deletion level was known. MtDNA deletion lev-
els from analysed samples were categorised into those with 
high levels (>60%), and those with low levels (<60%) i.e. 
the threshold mtDNA deletion level required for a biochem-
ical defect of the respiratory chain. The majority of mtDNA 
deletions encompass a region including MTND4 whilst 
MTND1 is relatively spared and thus mtDNA deletion levels 
were calculated through ΔCt (CtND1–ND4) using the formula 
(1–R) × 100 where R=2–ΔCt.13
For the purposes of comparing mtDNA copies, mem-
brane slides stained only for SDH were used for laser- 
microdissection and subsequent real-time PCR, given the 
interference of mtDNA copy number analysis by COX histo-
chemistry. Sequential sections placed on glass slides allowed 
for the identification of both respiratory enzyme-deficient 
and respiratory enzyme-intact muscle fibres on membrane 
slides. To counter any inter-individual variation of both total 
and wild-type mtDNA copies, the mean copies of 10 random 
respiratory enzyme-intact fibres were taken from each case. 
The copy number from each respiratory enzyme-deficient 
fibre was then divided by this value to give an mtDNA copy 
ratio for that case, as previously described.14
Long-range PCR was performed using primers covering 
the majority of the major arc, the primary site of mtDNA 
deletions, including the common deletion, and the Expand 
Long Template PCR system (Roche), as previously 
described.15 The DNA products were resolved on a 0.7% 
agarose gel with ethidium bromide. In addition to muscle, 
non-lesion CNS grey matter (15 µm × 100 µm × 100 µm) 
was laser microdissected and subjected to long-range PCR 
to confirm the excess of mtDNA deletions within the CNS 
in MS (except MS09, Supplementary Figure 1). The prod-
ucts from long-range PCRs indicating evidence of mtDNA 
deletions were extracted using a Qiagen gel extraction kit. 
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Sequencing of mtDNA breakpoints was carried out using an 
ABI 3130xl Genetic Analyser (Applied Biosystems) as pre-
viously detailed.3,15 Sequences were compared to the revised 
Cambridge Reference Sequence (rCRS) using Seqscape 
software.
Microscopy and quantitation
Quantitation of respiratory-intact and respiratory enzyme-
deficient muscle fibre density was carried out using a Zeiss 
Axioimager 2 at ×20 magnification and shown as a percentage 
of total muscle fibres. The analysis was performed blinded 
to disease state, case details and molecular findings (by IZ). 
The immunohistochemistry profile was achieved by using 
serial cryostat sections. As serial sections were also used 
for real-time PCR analysis, it enabled us to determine the 
immunoreactivity in relation to the molecular profile. 
Therefore, respiratory enzyme-deficient fibres were cate-
gorised into those with high or low level of mtDNA dele-
tions (>60%). Densitometry was carried out on grey-scale 
images and, to negate any inter-individuality, a ratio was 
determined for an individual by taking 10 random respira-
tory intact muscle fibres and used as a standard reference 
point in that individual. The cross-sectional area as well as 
the proportion of type I and type II muscle fibres, identified 
using myosin heavy chain slow and fast, respectively, were 
assessed by taking images at ×20 magnification and using 
Image J.
Table 1. Clinical details of the multiple sclerosis cases and controls.
Cases Age (gender) Tissue type Type of MS Disease duration 
(years)
Time from wheelchair 
(years)
PM time (hours)
MS01 40 M PM SP 23 23 18
MS02 44 F PM SP 10 10 9
MS03 45 F PM PP 20 13 18
MS04 46 M PM SP 20 7 12
MS05 47 F PM SP 13 10 27
MS06 49 F PM SP 23 11 7
MS07 49 F PM SP 17 NA 21
MS08 50 F PM SP NA NA 22
MS09 51 F PO RP 12 0 —
MS10 52 F PM SP 15 8 12
MS11 53 M PM PP 12 7 15
MS12 54 F PM SP 26 6 11
MS13 55 F PM SP 27 7 14
MS14 61 M PM SP 20 9 24
MS15 72 M PM SP 27 NA 23
MS16 75 M PM SP 32 16 22
MS17 82 F PM SP 45 14 15
CON01 42 F PO — — — —
CON02 42 M PO — — — —
CON03 51 M PO — — — —
CON04 52 F PO — — — —
CON05 53 M PO — — — —
CON06 57 F PM — — — 16
CON07 62 F PM — — — 21
CON18 64 M PM — — — 18
CON19 64 M PO — — — —
CON10 65M PO — — — —
CON11 71 M PM — — — 14
CON12 72 M PO — — — —
CON13 74 M PO — — — —
CON14 77 M PM — — — 26
CON15 82 M PM — — — 21
The mean age of MS cases (54.41 ± 11.63) was not significantly different from controls (61.87 ± 12.22, p = 0.09). None of the MS cases were on pre-
scribed disease-modifying therapy. The family history suggestive of a primary mitochondrial disorder was not documented in any of the cases. All MS 
cases contained mtDNA deletions in excess of age in non-lesion grey matter from either brain or spinal cord (Supplementary Figure 1) and satisfied 
MacDonald criteria 2001 for the diagnosis of MS.
MS: multiple sclerosis; M: male; F: female; CON: control (as previously described23); mtDNA: mitochondrial DNA; NA: not available; PM: post-mortem; 
PO: peri-operative; PP: primary progressive; RP: relapsing progressive; SP: secondary progressive.
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Statistical analysis
Parametric tests were used for statistical analysis. All statis-
tical comparisons were performed using Graph Pad Prism 
4, and t test and one-way analysis of variance (ANOVA) 
were used to compare two or more than two groups, respec-
tively. Post-ANOVA tests were carried out where a p value 
of <0.05 was observed. A p value of <0.05 was considered 
statistically significant.
Results
Respiratory enzyme-deficient muscle fibres in MS 
and controls
First, we identified respiratory enzyme-deficient muscle 
fibres using a well-established histochemical technique 
(COX/SDH histochemistry). Muscle fibres lacking com-
plex IV and with intact complex II are stained blue whereas 
those fibres with intact complex IV activity are stained 
brown (Figure 1(a) and (b)). A mean of 1059 muscle fibres 
were counted per case for both MS and control. The density 
of respiratory enzyme-deficient fibres in MS (6.85%±7.44) 
was not significantly different when compared with con-
trols (4.51%±3.39, p=0.48) (Figure 1(c)). The mean age of 
MS cases and controls was comparable (Table 1). There 
was a positive trend between the density of respiratory-
deficient fibres and age in MS and controls, which was not 
statistically significant (Figure 1(d)). The density of res-
piratory enzyme-deficient fibres did not correlate signifi-
cantly with either the disease duration or the duration of 
relative immobility judged by the time from wheelchair 
dependence (Supplementary Figure 2(a) and (b)). There 
Figure 1. Density of respiratory enzyme-deficient muscle fibres in multiple sclerosis and controls.
(a) and (b): Sequential complex IV (COX) and complex II (SDH) histochemistry revealed respiratory enzyme-deficient fibres (stained blue, lacking COX 
activity with intact SDH) in MS (a) and controls (b). The remaining muscle fibres showed variable intensity of complex IV staining (stained brown).
(c): Respiratory enzyme-deficient fibres accounted for a mean of 6.85%±7.44 of all muscle fibres in MS (n=17) compared with a mean of 4.51%±3.39 
in controls (n=15), which was not significantly different (p=0.48).
(d): There was a positive trend between the density of respiratory enzyme-deficient fibres and age in MS (p=0.29, r2=0.07) and controls (p=0.07, 
r2=0.32). In MS, this was statistically significant when the three outlying cases (MS04, MS14 and MS15) were excluded (p=0.038, r2=0.312 not shown).
COX: cytochrome c oxidase; SDH: succinate dehydrogenase; MS: multiple sclerosis. + indicates the mean value. Box plots indicate 25th and 75th 
centiles with median value by the horizontal line and fifth to 95th centiles by the error bars.
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were three outlying MS cases with respiratory deficiency 
exceeding the upper limit of the 95% confidence intervals 
of controls (MS04, MS14 and MS15).
Muscle fibre size and type in MS and controls
The cross-sectional area of the respiratory enzyme-deficient 
muscle fibres did not significantly differ when compared to 
fibres with intact complex IV activity in both MS cases and 
controls (p=0.059 and p=0.258, respectively). However, the 
cross-sectional area of both type I and type II muscle fibres 
in MS was significantly lower compared with controls (data 
not shown). Furthermore, there was a predominance of type 
I fibres in controls, accounting for 82.30% of all muscle 
fibres whereas the proportion of type I fibres was signifi-
cantly decreased to 61.48% in MS (p=0.006 not shown).
Mitochondrial subunit profile of respiratory-
deficient muscle fibres in MS
To assess both mtDNA and nuclear DNA-encoded subunits of 
the mitochondrial respiratory chain at a single fibre level in 
MS cases and controls, we tracked the respiratory enzyme-
deficient muscle fibres and those with intact complex IV activ-
ity in serial sections (Figure 2(a–d)). There was a significant 
decrease in COX-I (Figure 2(e)) and complex I-20kDa (Figure 
2(f)) immunoreactivity in respiratory enzyme-deficient fibres, 
compared with fibres with intact complex IV activity, in both 
groups. The extent of subunit loss in respiratory enzyme-defi-
cient fibres in MS, detected by immunohistochemistry, how-
ever, was not significantly different compared with controls. 
This was also the case when the respiratory enzyme-deficient 
fibres harbouring high- (>60%) and low-level mtDNA dele-
tions were analysed separately in MS and controls.
MtDNA deletion level in respiratory enzyme-
deficient muscle fibres from MS and controls
Next, we determined whether the level of mtDNA deletions 
in single fibres, analysed using real-time PCR and confirmed 
by long-range PCR and sequencing, and the percentage of 
fibres harbouring high levels of mtDNA deletions were dif-
ferent between MS and controls (Figure 3). The mean level 
of mtDNA deletions found within respiratory enzyme- 
deficient fibres in MS was 45.06% ± 26.35, which was not 
significantly different compared with controls (40.35% ± 
42.02, p=0.38). This, however, identified two separate pop-
ulations of respiratory enzyme-deficient cells: those with 
above threshold or high level of mtDNA deletions (>60%), 
sufficient to cause a biochemical defect, and others with a 
below threshold or low level of mtDNA deletions. When 
these two populations were analysed separately, the mtDNA 
deletion levels in fibres with high- or low-level mtDNA 
deletions were not significantly different in MS cases com-
pared with the corresponding fibres from controls (Figure 
3(b)). When MS cases and controls were segregated by age 
(below and above 60), the difference in mtDNA deletion 
level between the two groups was not significantly differ-
ent for <60 (43.95% ± 20.54 versus 39.45% ± 19.42 in MS 
and controls, respectively, p=0.84) and > age 60 (43.55% ± 
22.82 versus 39.53% ± 17.93 in MS and controls, respec-
tively, p=0.74). As expected, the mtDNA deletion level in 
all the muscle fibres with intact complex IV activity was 
<60%. The long-range PCR findings in fibres with high-
level mtDNA deletions were consistent with clonal expan-
sion in both MS and controls (Supplementary Figure 3 and 
Supplementary Table 2). When the percentage of respira-
tory-deficient fibres harbouring high levels of mtDNA 
deletions per case was determined, it did not significantly 
differ between the two groups as a whole (45.66% and 
36.85% in MS and controls, respectively, p=0.35) or when 
segregated by age (below and above 60) and it did not cor-
relate with age, disease duration, time from wheelchair 
bound or the density of respiratory enzyme deficiency 
(Figure 3(c) and Supplementary Figure 2(c–f)).
We then determined whether the total mtDNA and 
wild-type mtDNA copies in respiratory enzyme-deficient 
muscle fibres were different between MS and controls 
(Figure 4). As expected, the total mtDNA copies, which 
includes both mutant and wild-type, was significantly 
greater while the wild-type mtDNA copies were signifi-
cantly lower in fibres harbouring high-level mtDNA dele-
tions (p<0.0001), indicating clonal expansion of mtDNA 
deletions in both MS and controls. However, we did not 
detect a significant decrease in either total or wild-type 
mtDNA copies within these two subtypes of respiratory 
enzyme-deficient fibres (those with high- and low-level 
mtDNA deletions) in MS compared with controls, despite 
the respiratory enzyme deficiency in these fibres with low 
level mtDNA deletions and the difference in ambulation 
between MS cases and controls.
Discussion
A comprehensive analysis of single muscle fibres did not 
identify a significant mitochondrial abnormality at the level 
of respiratory chain activity, expression of subunits of mito-
chondrial respiratory chain subunits and mtDNA in pro-
gressive MS cases. Our findings do not support the 
existence of a mitochondrial genetic abnormality as part of 
a diffuse multisystem disorder in cases with classical MS.
The co-existence of an MS-like phenotype with a pri-
mary mitochondrial disorder, due to a mutation in mtDNA 
or nuclear DNA-encoding mitochondrial proteins, has 
raised the possibility of a diffuse multisystem mitochon-
drial abnormality in MS. These cases include Harding’s 
disease, where the MS-like phenotype co-exists with 
Leber’s Hereditary Optic Neuropathy (LHON), and others 
where the primary mitochondrial disorder was due to a 
mutation in the optic atrophy 1 (OPA1) gene, mitochondrial 
tRNA(IIe) gene and mtDNA polymerase gamma (POLG1) 
gene, among others.16–20 In our study, two of the three MS 
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Figure 2. Immunohistochemical profile of mitochondrial respiratory chain subunits in multiple sclerosis muscle.
(a–d): In serial sections and in relation to the mitochondrial respiratory chain activity determined by COX/SDH histochemistry (a), the status of mito-
chondrial DNA (b, complex IV subunit-I) and nuclear DNA ((c) and (d)), complex I 20-KDa and complex II 70-KDa)-encoded mitochondrial subunits 
was determined using immunohistochemistry in MS cases (a–d) and controls (not shown). In the majority of respiratory enzyme-deficient muscle fibres 
(stained blue in (a), arrows and insert) the mitochondrial DNA-encoded subunit, COX-I (b), showed low-intensity staining whilst complex II-70kDa 
staining remained intact or was increased (d).
(e) and (f): When single muscle fibres were analysed by densitometry, the loss of both COX-I (Ei, p<0.001) and complex I-20kDa (Fi, p<0.001) in respira-
tory enzyme-deficient fibres (stained blue) was found to be significant. When fibres containing high-level (>60%) and low-level mtDNA deletions were 
analysed separately, we did not detect a significant difference in COX-I (Eii) or complex I 20 kDa (Fii) immunoreactivity between MS cases (n=17) and 
controls (n=15). On average 20 fibres were analysed per case for both MS and controls.
CON: control; COX: cytochrome c oxidase; mtDNA: mitochondrial DNA; Neg: negative or deficiency of complex IV with intact complex II (stained 
blue); Pos: intact respiratory enzyme activity (stained brown); SDH: succinate dehydrogenase. + indicates the mean value. Box plots indicate 25th and 
75th centiles with median value by the horizontal line and fifth to 95th centiles by the error bars.
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Figure 3. Level of mtDNA deletions in single laser 
microdissected muscle fibres in multiple sclerosis and controls.
(a): Single respiratory enzyme-deficient fibres (COX negative, stained blue) 
in MS (370 fibres from 17 cases) showed a mean mtDNA deletion level 
of 45.06% ± 26.35 (a), while the respiratory enzyme-deficient fibres in 
control (358 fibres from 15 controls) contained a mean mtDNA deletion 
level of 40.35% ± 42.02, p=0.38), which was not significantly different. 
In both MS and controls, respiratory enzyme-deficient fibres contained 
significantly greater mtDNA deletion level (p<0.0001) than fibres with 
intact respiratory enzyme activity (stained brown, 4.74% ± 6.93, in MS and 
5.06% ± 10.48 in controls). The scatter plots revealed two populations of 
respiratory enzyme-deficient fibres in both MS and controls.
(b): When the respiratory enzyme-deficient fibres (COX negative, 
stained blue) harbouring high-level mtDNA deletions were considered 
separately from those containing low-level mtDNA deletions (<60%), 
the level of mtDNA deletions in neither high- nor low-level fibres was 
significantly different between MS (n=17) and controls (n=15).
(c): The percentage of respiratory enzyme-deficient fibres containing high 
level mtDNA deletions (>60%) was determined per case. Although MS 
cases had a tendency to show a greater percentage than controls (mean 
of 45.66% in MS and 36.85% in controls), the difference was not statisti-
cally significant (p=0.35). On average, 20 respiratory enzyme-deficient 
fibres were analysed per MS case and control by real-time PCR.
MS: multiple sclerosis; CON: control; COX: cytochrome c oxidase; 
mtDNA: mitochondrial DNA; Neg: negative or deficiency of complex IV 
with intact complex II (also termed respiratory enzyme deficient); Pos: 
intact respiratory enzyme activity; PCR: polymerase chain reaction.
cases in which the respiratory enzyme-deficient muscle 
fibres were prominent had clinical features not usually 
associated with MS: Gille de la Tourette syndrome (MS04) 
and retinal vasculitis (MS15). However, these clinical con-
ditions, where mitochondrial dysfunction has been impli-
cated (genetic association studies identified an inner 
mitochondrial membrane peptidase in Gille de la Tourette 
syndrome and retinal vasculitis may be a presenting feature 
of patients with LHON), are not typical or frequent in pri-
mary mitochondrial disorders.21,22 Although the case reports 
have suggested the co-existence of a primary mitochondrial 
disorder with MS as a more frequent occurrence than antic-
ipated by chance, there is no convincing evidence for an 
aetiological link between pathogenic mitochondrial genetic 
abnormalities in non-CNS tissue and classical MS, to which 
our findings also provide support.
Our assessment was limited to paraspinal muscle 
because ethical considerations prevented the sampling of 
limb skeletal muscle at post-mortem, which was necessary 
to procure either brain or spinal cord tissue to confirm the 
existence of mitochondrial abnormalities in the CNS. We 
previously reported the age-related mitochondrial changes 
within paraspinal muscle from both post-mortem cases and 
patients undergoing spinal surgery.23 Our negative findings 
in MS paraspinal muscles, which can harbour high level of 
mtDNA deletions in primary mitochondrial disorders,24 are 
supported by a study of open biopsies of quadriceps muscle 
from MS patients.25 Understandably, CNS mitochondria 
could not be investigated in patients who underwent muscle 
biopsy. Despite a decrease in complex I activity in muscle, 
they did not detect mtDNA deletions in the isolated mito-
chondria. The lack of histochemical techniques to identify 
complex I-deficient cells hampers the single cell-based 
analysis of mtDNA, that we and others have used success-
fully to interrogate complex IV deficient cells. In a separate 
study of vastus lateralis muscle, lactate level, reflecting an 
underlying mitochondrial dysfunction, was not elevated in 
the microdialysate from MS patients.26 Together, these 
findings do not support the existence of pathogenic levels 
of mtDNA deletions in excess of age-related changes within 
muscle in MS.
The significant morphological changes of muscle fibres 
(atrophy and fibre-type switching) that we observed in post-
mortem tissue from MS cases are most likely related to mus-
cle deconditioning due to the neurological impairment.27,28 
However, this difference in ambulatory capacity between 
the two groups is unlikely to have given a false-negative 
result (mask a mtDNA deletion led mitochondrial abnormal-
ity in excess of age in progressive MS cases). Wild-type 
mtDNA may deplete in disused and deconditioned muscle 
and such a decrease in wild-type mtDNA copiesin muscle 
fibres would have caused an apparent increase in the per-
centage of mtDNA deletions within single fibres in MS (i.e. 
a false-positive result rather than a false-negative). Our 
study did not show an apparent loss of mtDNA copies, total 
or wild-type, in MS cases compared with controls. This may 
be because continual use of ATP irrespective of ambulatory 
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capacity in the isotonic paraspinal muscles, in contrast to the 
phasic skeletal limb muscles, minimises the impact of dis-
use on the mitochondria in paraspinal muscles. Furthermore, 
rigorous exercise and resistance training was needed to 
decrease the level of mtDNA deletions in patients with pri-
mary mitochondrial disease.29,30
Given that mitochondrial abnormalities within the CNS are 
an established feature of MS, the next challenges in this field 
are to understand the mechanisms that cause mitochondrial 
damage in progressive MS, particularly to mtDNA, and deter-
mine the consequences of the mitochondrial abnormalities for 
its pathophysiology. Although mitochondrial abnormalities 
have been described in experimental autoimmune encephalo-
myelitis (EAE) and mitochondria have been therapeutically 
targeted in animal models of MS, mtDNA deletions have not 
yet been studied in these models.2,31 Investigation of mtDNA 
from the CNS in the existing and new animal models of MS 
may pave the way to identifying potential novel ways to pre-
vent respiratory enzyme deficiency and identify therapeutic 
targets for patients with progressive MS.
In summary, a detailed analysis did not identify an 
excess of respiratory enzyme-deficient fibres, respiratory 
chain subunit loss or mtDNA deletions in muscle from pro-
gressive MS cases. These findings, which do not provide 
support to the existence of a diffuse mitochondrial abnor-
mality involving multiple systems in MS, highlight the 
need to investigate the cause(s) of mitochondrial abnormal-
ities, particularly mtDNA deletions, thus far described 
within neurons in progressive MS.
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